Health screening is one of the most visible activities in preventive healthcare across Asia. Governments subsidise national programmes, hospitals hold community screening days, pharmacies offer blood pressure and glucose checks, and private providers sell annual screening packages to individuals and employers. When these programmes report their progress, the figure most often quoted is the simplest one: how many people were screened.

That figure matters. It is also incomplete. A screening test does not improve anyone’s health on its own. It is the first step in a chain that has to end with the right people receiving timely assessment and appropriate care. Every link in that chain can fail, and a programme can screen very large numbers while delivering little benefit, or even causing avoidable harm.

Why the Number Screened Is an Incomplete Measure

The case for screening in Asia is real. Malaysia’s National Health and Morbidity Survey 2023 found diabetes in 15.6% of adults. Only 9.7% had known diabetes, while 5.9% had raised blood glucose without a known diagnosis. Hypertension showed a similar pattern: 29.2% overall, with 11.9% of adults having raised blood pressure without a known diagnosis. The survey also found a higher proportion of undiagnosed conditions among younger adults. Survey measurements taken on a single occasion are not the same as a clinical diagnosis, but they indicate a substantial group who may benefit from being identified and assessed.

The purpose of screening, however, is not detection for its own sake. The World Health Organization’s Regional Office for Europe describes screening as a way of identifying people at higher risk within an apparently healthy population so that earlier intervention can reduce the incidence or mortality of a condition. The same guidance warns that screening brings harms as well as benefits. It also warns that the ability to perform a test does not mean it should be performed, and that screening decisions need protection from commercially driven demand.

These principles have a long history. The screening criteria published by Wilson and Jungner for WHO in 1968 asked whether a condition is important, whether it can be detected early, and whether acceptable treatment exists. Later reviews extended the thinking to the programme level, including defined target populations, quality assurance, informed choice, equity of access and planned evaluation.

The Screening Cascade: Where Programmes Lose People

A useful way to assess any screening programme is to follow participants through each stage and measure how many move to the next step. We call this the screening cascade:

1. Eligible population defined. Who should be screened, based on age, sex, risk factors and the recommended interval since the last screen?
2. Invitation or outreach. What proportion of the eligible population was actually reached?
3. Screening completed. Coverage among the eligible population, not just a raw headcount.
4. Test quality assured. Were tests performed, processed and reported to a consistent standard?
5. Result communicated. Did every participant receive and understand their result, including normal results and advice on the next screening date?
6. Abnormal results referred. Was every abnormal finding routed to a clinician or assessment service?
7. Follow-up completed. Did people with abnormal results attend diagnostic assessment within a reasonable time?
8. Linked to ongoing care. Were confirmed conditions brought under appropriate management?
9. Rescreened appropriately. Were people with normal results invited back at the recommended interval, rather than too soon or not at all?

A programme reporting only stage three can look successful while losing most of its value at stages five to eight. The largest drop-off often occurs after an abnormal result, when responsibility passes from the screening provider to the patient or to another part of the health system.

What Published Follow-Up Data Can Show

Few screening programmes in the region publish follow-up data, which makes Singapore’s reporting a useful reference. In a 2021 parliamentary reply, the Ministry of Health said that about 40% of people screened for cardiovascular risk under the Screen for Life programme had abnormal results. It also said that follow-up rates among them rose from 56% in 2016 to over 85% in 2020, following enhancements to screening subsidies in 2017. The data show that follow-up improved over the period. They do not by themselves establish which factors were responsible.

The same reply broke participants down by ethnicity. That kind of disaggregation lets planners compare who is being screened with the make-up and risk profile of the wider population, and it is how equity gaps become visible.

Singapore’s current Healthier SG Screening protocols also illustrate a deliberately designed follow-up pathway. For colorectal cancer screening using faecal immunochemical tests (FIT), programme coordinators contact people with abnormal results directly to arrange assessment appointments. General practitioners are encouraged to follow up with patients to close each screening episode, including advising on the next screening cycle. The point for other providers is not to copy a national system. It is to decide in advance who owns each step after the test.

A Practical Metrics Framework

The table below summarises measures that give a fuller picture of programme performance. Not every provider can collect all of them, but each one answers a question the headcount cannot.

Metric	What It Shows	What It Does Not Show
Number of people screened	Programme reach and operational capacity	Whether the right people were screened, or whether anyone benefited
Coverage of the eligible population	How well the programme reaches its intended target group	Quality of testing or follow-up
Proportion screened outside recommended criteria	Possible over-screening and wasted resources	Individual clinical judgement in specific cases
Abnormal result rate	Test yield and the expected demand for follow-up services	Confirmed disease; many abnormal results are false positives
Follow-up completion rate	Whether abnormal findings lead to assessment	Whether assessment led to effective treatment
Time from abnormal result to assessment	Speed and capacity of the referral pathway	Long-term health outcomes
Linkage to ongoing care	Whether detected conditions come under management	Adherence or control over time
Participation by income, ethnicity, age and location	Equity of access	Reasons for non-participation

Measuring Harms, Not Only Benefits

Screening harms are easy to overlook because they rarely appear in promotional material. They include false-positive results that cause anxiety and lead to further tests, and false reassurance from false-negative results. They also include overdiagnosis, meaning the detection of conditions that would never have caused symptoms, as well as complications from follow-up procedures and the diversion of clinical capacity away from people who need it more.

A responsible programme tracks indicators such as the proportion of abnormal screens not confirmed on assessment, the number of invasive follow-up procedures performed, and complaints related to result communication. These figures are not signs of failure. They show that a programme understands its own trade-offs.

Questions for Private Providers and Corporate Screening Packages

Private hospitals, clinic groups and corporate wellness providers deliver a large share of health screening in many Asian markets. Their packages often include tests beyond those recommended in national screening programmes. Before expanding or marketing a package, providers can ask:

• Is each test in the package supported by current clinical guidance for the age and risk group it is offered to?
• Who reviews every abnormal result, and how quickly is the participant contacted?
• Is there a documented referral pathway for each type of abnormal finding?
• Are participants told, before testing, that screening tests have limitations and can produce false results?
• Does the provider track follow-up completion, or does responsibility end when the report is issued?
• Are employer clients given aggregated, privacy-protected reports rather than individual results?
• Do promotional materials avoid implying that screening prevents disease on its own?

Providers who can answer these questions clearly are better placed to earn the trust of clinicians, employers and regulators. The same discipline applies to how results are publicised. Our analysis of documenting large-scale health campaigns credibly explores this in more detail.

When Screening Scale Becomes a Documented Achievement

Some screening initiatives reach a scale that is noteworthy in its own right. Examples include a hospital group screening an exceptional number of residents within a defined period, a pharmacy network running simultaneous checks across many outlets, or a community programme reaching large numbers of underserved participants. When the count is precisely defined and independently evidenced, such milestones can be documented through record recognition.

For organisations weighing an Asia Record application, or asking how to get an Asia Record for a screening initiative, the requirements closely mirror good programme reporting. The process for record certification in Asia set out by Asia Record starts with defining exactly what is being claimed. It then sets the conditions of measurement, such as dates, locations and participants, and asks for evidence that allows the claim to be assessed. A provider that already tracks eligibility criteria, test dates, sites and participant numbers has most of that evidence in hand.

The limits of such recognition should be stated plainly. Becoming an Asia Record holder for a screening initiative documents its measurable scale. It is a form of business achievement recognition for hospital groups and healthcare businesses. It does not show that the programme improved health outcomes, that its tests were clinically appropriate, or that its follow-up was effective. Those claims require separate clinical and programme evidence. Recognition also does not replace ministry licensing, laboratory accreditation or any regulatory approval a screening service must hold. Our explainer on what accreditation, awards and records each prove sets out these distinctions.

Reporting a Screening Programme Honestly

A credible screening report should include at least three things. The first is reach, expressed against the eligible population rather than as a standalone number. The second is the follow-up pathway, including what share of abnormal results reached assessment and how long that took. The third is an honest account of limitations, including known harms and groups the programme did not reach.

For health systems facing a large burden of undiagnosed chronic disease, better screening is worth pursuing. Its value is decided after the test, by whether people with abnormal results are assessed and cared for, and whether people with normal results are spared unnecessary intervention. Programmes that measure those stages give policymakers, clinicians and the public a far more useful account than a headcount alone. The same logic applies to broader measures of primary care access beyond visit volume.

Note: This article is for general informational purposes and does not replace professional medical advice. Individuals should discuss which screening tests are appropriate for them with a qualified healthcare professional.